S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
OTCMKTS:CHGCY

Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis

$19.13
-0.43 (-2.20%)
(As of 03/28/2024 ET)
Today's Range
$18.45
$19.65
50-Day Range
$17.15
$21.94
52-Week Range
$11.93
$22.61
Volume
38,068 shs
Average Volume
87,993 shs
Market Capitalization
$62.94 billion
P/E Ratio
27.33
Dividend Yield
0.52%
Price Target
N/A

Chugai Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
5.71%
From $0.70 to $0.74 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.64 out of 5 stars

CHGCY stock logo

About Chugai Pharmaceutical Stock (OTCMKTS:CHGCY)

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

CHGCY Stock Price History

CHGCY Stock News Headlines

Chugai Pharmaceutical Co Ltd (CUP.HA)
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Chugai Pharmaceutical Co., Ltd. (CHGCY)
Chugai Pharmaceutical Co. Ltd. ADR
Chugai Pharmaceutical Co Ltd (CUP.MU)
Chugai Pharmaceutical Co., Ltd. (4519)
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
U.S. Stocks Rise as Economic Growth Continues
U.S. Stocks Rise After Strong GDP Data
Futures Steady With More Earnings in Focus
Nikkei Down 0.3%, Dragged by Tech, Pharmaceutical Stocks
Chugai Pharmaceutical Co Ltd ADR CHGCY
Chugai Pharmaceutical Co., Ltd. (CUP0.MU)
Chugai Pharmaceutical Co Ltd CUP
Chugai Pharmaceutical Co Ltd
Chugai Pharmaceutical earnings: here's what to expect
TOPIX Pharmaceutical (IPHAM.T)
Chugai Pharmaceutical Co. Ltd.
Here's what to expect from Chugai Pharmaceutical's earnings report
CHGCY Chugai Pharmaceutical Co., Ltd.
See More Headlines
Receive CHGCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chugai Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/01/2024
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drugs, proprietaries, & sundries
Sub-Industry
N/A
Current Symbol
OTCMKTS:CHGCY
Fax
N/A
Employees
7,771
Year Founded
N/A

Profitability

Net Income
$2.31 billion
Pretax Margin
39.94%

Debt

Sales & Book Value

Annual Sales
$7.93 billion
Cash Flow
$0.86 per share
Book Value
$3.51 per share

Miscellaneous

Outstanding Shares
3,289,980,000
Free Float
N/A
Market Cap
$62.94 billion
Optionable
Not Optionable
Beta
0.80
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Osamu Okuda (Age 61)
    President, CEO & Representative Director
    Comp: $1.48M
  • Mr. Toshiaki Itagaki (Age 64)
    Head of Finance Supervisory Division, CFO, Executive VP & Director
  • Toshiya Sasai
    Executive of Investor Relations Group & Corporate Communications Department
  • Mr. Shinji Hidaka
    Executive VP and Head of Marketing & Sales Division
  • Mr. Junichi Ebihara
    Executive Vice President
  • Dr. Yoshiaki Ohashi (Age 64)
    SVP & Full-time Audit Supervisory Board Member
  • Mr. Tetsuya Yamaguchi
    Executive VP and Head of Project, Lifecycle Management & Foundation Medicine Unit
  • Mr. Yoshiyuki Yano
    Executive Vice President
  • Ms. Satoko Shisai (Age 61)
    Executive VP & Head of Digital Transformation Unit
  • Dr. Shigehiro Yamada Ph.D. (Age 60)
    Head of Sustainability Department and Full-Time Audit & Supervisory Board Member

Should I Buy Chugai Pharmaceutical Stock? CHGCY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Chugai Pharmaceutical Co., Ltd.:

  • Chugai Pharmaceutical has a strong portfolio of oncology products, including Avastin, Tecentriq, and Herceptin, which are in high demand globally due to their effectiveness in treating various types of cancer.
  • The company has shown consistent growth in revenue and earnings, with a strong net margin of 29.14% and a return on equity of 21.02%, indicating efficient operations and profitability.
  • Chugai Pharmaceutical's stock price has been on an upward trend, reaching a 52-week high of $22.61, reflecting positive investor sentiment and potential for capital appreciation.
  • Strategic alliances and collaborations with Roche Group provide Chugai Pharmaceutical with access to resources, expertise, and a broader market reach, enhancing its competitive position in the pharmaceutical industry.
  • The company's focus on research and development across various therapeutic areas, such as oncology, immunology, and neuroscience, positions it well for future growth and innovation in the healthcare sector.

Cons

Investors should be bearish about investing in Chugai Pharmaceutical Co., Ltd. for these reasons:

  • Chugai Pharmaceutical's stock experienced a significant increase in short interest, indicating potential market volatility and uncertainty surrounding investor sentiment towards the company.
  • The pharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact Chugai Pharmaceutical's product development pipeline and market access in the future.
  • Market fluctuations and macroeconomic factors may affect the company's financial performance and stock price, leading to investment risks for shareholders.
  • Dependency on a few key products, such as Avastin and Herceptin, for a significant portion of revenue poses concentration risk and vulnerability to changes in market demand or competition.
  • Global health crises, regulatory changes, or unexpected events could disrupt Chugai Pharmaceutical's operations and supply chain, affecting its financial stability and investor confidence.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, March 25, 2024. Please send any questions or comments about these Chugai Pharmaceutical pros and cons to contact@marketbeat.com.

CHGCY Stock Analysis - Frequently Asked Questions

Should I buy or sell Chugai Pharmaceutical stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chugai Pharmaceutical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CHGCY shares.
View CHGCY analyst ratings
or view top-rated stocks.

How have CHGCY shares performed in 2024?

Chugai Pharmaceutical's stock was trading at $18.85 at the beginning of 2024. Since then, CHGCY shares have increased by 1.5% and is now trading at $19.13.
View the best growth stocks for 2024 here
.

Are investors shorting Chugai Pharmaceutical?

Chugai Pharmaceutical saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 20,600 shares, a decrease of 17.6% from the February 29th total of 25,000 shares. Based on an average daily volume of 135,600 shares, the days-to-cover ratio is presently 0.2 days.
View Chugai Pharmaceutical's Short Interest
.

How were Chugai Pharmaceutical's earnings last quarter?

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) announced its quarterly earnings data on Thursday, February, 1st. The company reported $0.19 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.01. The company had revenue of $1.85 billion for the quarter. Chugai Pharmaceutical had a trailing twelve-month return on equity of 21.02% and a net margin of 29.14%.

Is Chugai Pharmaceutical a good dividend stock?

Chugai Pharmaceutical (OTCMKTS:CHGCY) pays an annual dividend of $0.10 per share and currently has a dividend yield of 0.50%. The dividend payout ratio is 14.29%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CHGCY will have a dividend payout ratio of 13.51% next year. This indicates that the company will be able to sustain or increase its dividend.

How do I buy shares of Chugai Pharmaceutical?

Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CHGCY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners